In CSCs and cancer-initiating cells, a concomitant administration of a specific HSP40 subfamily protein, DnaJB8-cytotoxic T lymphocyte-mediated immune escape, is used in the immune-editing program to promote tumor recurrence, maintain tumors, and support metastasis [250]. The gene discussed is DNAJB1; the disease is cancer.